APOE and Alzheimer disease: Some studies reported that IDE levels, as well as Aβ degradation, tend to decrease in the hippocampus and CSF of patients with AD which is more significant in APOE e4 carriers (Cook et al., 2003[10]; Del Campo et al., 2015[15]; Son et al., 2016[85]).